Citius Chairman and CEO
EF Hutton Annual Global Conference Details
Format: In-person one-on-one meetings (no general presentations)
Location:
Registration: Visit the conference website
H.C. Wainwright 2nd Annual BioConnect Investor Conference Details
Presentation:
Format: Presentations and one-on-one meetings
Location: Nasdaq Global Headquarters,
Registration: Visit the conference website
Please note that the presentation date and time are subject to change. Participants should refer to the final program agenda for up-to-date information.
About
Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company s diversified pipeline includes two late-stage product candidates. At the end of 2023, Citius completed enrollment in a Phase 3 pivotal superiority trial of Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. The Biologics License Application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma, is currently under review by the FDA with
Contact:
Email: ir@citiuspharma.com
Tel: 908-967-6677
(C) 2024 Electronic News Publishing, source